Yang Z, Feng J, Xiao L, et al. - This study was undertaken to determine if PGLYRP2 was able to influence hepatocellular carcinoma (HCC) progression through regulating host antitumor immune responses. According to the results, tumor-derived PGLYRP2 acts as a candidate biomarker for adequate immune response against HCC and improved patient results, showing the significance of hepatic PGLYRP2 in cancer immunosurveillance and in designing novel immunotherapeutic approaches.